Testing effectiveness (Phase 2)Looking for participantsNCT06716658
What this trial is testing
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Who this might be right for
Lymphoma, T-CellNK-LGL LeukemiaT-LGL Leukemia+7 more
Institute of Hematology & Blood Diseases Hospital, China 48